Nuevolution in drug discovery collaboration with Janssen

Nuevolution today announced that it has entered into collaboration with Janssen Biotech that will focus on the discovery and development of new medical entities for the treatment of oncological, infectious and inflammatory diseases.

Within the framework of the collaboration, Nuevolution will apply its drug discovery platform Chemetics to discover and advance drug candidates against drug targets of interest to Janssen. Chemetics, a unique, patent protected hybrid of proven wet chemistry and molecular biology, enables rapid oligonucleotide e.g. DNA encoded synthesis of up to billions of chemically diverse drug-like small molecule compounds, and the efficient screening and optimisation of these, facilitating the identification of potent drug leads at unprecedented speed and scale.

Nuevolution eligible to milestone payments

Under the terms of the agreement with Janssen Biotech, Nuevolution will receive an upfront payment, research funding and would be eligible to milestone payments upon achievement of specified research, development and commercial milestones. In addition, Nuevolution would be entitled to receive certain royalty payments on net-sale of products that may be commercialised as a result of the collaboration.

“We are excited about entering into the extensive collaboration with Janssen,” said Alex Gouliaev, CEO of Nuevolution and continued, “We are looking forward to an excellent working relationship with their dedicated research and development teams.”